Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2018-11-20 Share Issue/Capital Cha…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, the impact on total share capital, and the regulatory compliance with the Danish Capital Markets Act. This fits the definition of a 'Share Issue/Capital Change' (SHA) announcement, as it describes a specific change in the company's capital structure.
2018-11-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the resulting change in the company's total share capital. This falls directly under the category of share issues and capital changes.
2018-11-20 English
Legal Proceedings Report 2018
Legal Proceedings Report Classification · 99% confidence The document is titled "Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma" and contains key clinical trial results (PFS data, HR) and management commentary. It is a formal announcement of financial/clinical progress, not a full regulatory report (like 10-K or IR). It is too detailed to be a simple Report Publication Announcement (RPA) which usually just points to an attached report. Since it is a press release announcing specific, material clinical trial results, it best fits the Earnings Release (ER) category, which often covers key operational/clinical milestones alongside or instead of quarterly financials, or potentially Investor Presentation (IP) if it were structured as slides, but this is a news release format. Given the focus on announcing 'topline results' and key data points, ER is the most appropriate fit among the options for a material announcement of performance indicators, even if not strictly quarterly earnings.
2018-10-29 English
Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding positive topline results from a Phase III clinical trial (MAIA study). It provides key highlights of the study's primary endpoint, safety profile, and future regulatory plans. It does not contain full financial statements, nor is it a report publication announcement (it is the announcement of the results themselves). As it is a general regulatory announcement regarding company news that does not fit into specific categories like Earnings Release or M&A, it is classified as a Regulatory Filing (RNS).
2018-10-29 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is titled "Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma" and is explicitly labeled as a "Company Announcement." It details the positive results of a clinical trial (Phase III CASSIOPEIA study) and mentions that data will be discussed with health authorities for potential regulatory filings. This type of announcement, which releases key preliminary results before a full regulatory filing or comprehensive report, aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of clinical trial results, which often precedes a formal Earnings Release or Investor Presentation, and it is not a full financial report (10-K, IR) or a transcript (CT), it functions as a high-level corporate update. Given the options, this is a specific corporate announcement of material information, which often falls under the scope of an Earnings Release (ER) if it were quarterly results, but here it is a clinical trial update. However, in the context of financial reporting databases, major clinical trial updates that impact valuation are often categorized as a form of Earnings Release or a specific Regulatory Filing. Since it is a direct announcement of results and not a presentation (IP) or a formal regulatory document (10-K, AR), and it is not a general regulatory filing (RNS), the closest fit for a material, time-sensitive corporate update announcing performance metrics (even clinical ones) is ER, or if we strictly interpret it as a non-financial regulatory update, RNS. Given the context of financial impact ("Today's news does not impact Genmab's 2018 financial guidance"), it functions similarly to an ER. However, since it is a 'Company Announcement' detailing clinical trial progress rather than financial performance metrics (revenue, EPS), RNS (Regulatory Filings - general fallback) is a safer classification for non-standard material announcements, or we can consider it an Investor Presentation (IP) if it were a presentation, but it reads like a press release. Given the options, and recognizing this is a press release announcing key operational/clinical milestones, RNS is the most appropriate general category for non-standard, material corporate announcements that aren't explicitly defined elsewhere (like DIV, CAP, etc.). I will classify it as RNS as it is a general regulatory/company announcement that doesn't fit the specific financial report codes.
2018-10-21 English
Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding positive topline results from a Phase III clinical trial (CASSIOPEIA). It provides a summary of the trial results, quotes from the CEO, and background information on the drug and disease. While it contains detailed clinical information, it is structured as a press release/announcement (indicated by the 'Company Announcement' header, contact information, and the 'Attachment' section at the end). According to the 'Menu vs Meal' rule, since this is an announcement of results rather than a full regulatory filing or a comprehensive financial report, and it explicitly lists an attachment for the full details, it falls under the Regulatory Filings (RNS) category as a general corporate announcement.
2018-10-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.